These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 15808584

  • 1. Preliminary evaluation of a new chemiluminescence assay (Liaison Cyclosporine; DiaSorin Laboratories) allowing both C0 and C2 cyclosporine levels determination: comparison with RIA method.
    Olejnik Y, Elaerts S, Bonardet A, Chong G, Mourad G, Cristol JP, Dupuy AM.
    Transplant Proc; 2005; 37(1):172-4. PubMed ID: 15808584
    [Abstract] [Full Text] [Related]

  • 2. The V-twin system (Dade Behring Laboratories): a useful tool for immunosuppressive drug monitoring.
    Elaerts S, Olejnik Y, Bonardet A, Garrigue V, Mourad G, Cristol JP, Dupuy AM.
    Transplant Proc; 2005; 37(1):167-71. PubMed ID: 15808583
    [Abstract] [Full Text] [Related]

  • 3. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 4. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring.
    Ventura E, Bonardet A, Pageaux GP, Mourad G, Cristol JP.
    Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963
    [Abstract] [Full Text] [Related]

  • 5. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB, Angelini A, Alaibac M, Bontorin M, Calzolari D, Peserico A, Thiene G, Iliceto S, Gerosa G.
    Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
    [Abstract] [Full Text] [Related]

  • 6. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 7. Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation.
    Cattaneo D, Zenoni S, Murgia S, Merlini S, Baldelli S, Perico N, Gotti E, Ottomano C, Crippa A, Remuzzi G.
    Clin Chim Acta; 2005 May; 355(1-2):153-64. PubMed ID: 15820490
    [Abstract] [Full Text] [Related]

  • 8. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K, Fauchald P, Bergan S, Høieggen A, Hallan S, Svarstad E, Bergrem H, Eriksen BO, Pfeffer PF, Dalen I, Leivestad T.
    Transplantation; 2003 Oct 27; 76(8):1236-8. PubMed ID: 14578761
    [Abstract] [Full Text] [Related]

  • 9. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA, Veinot JP, Williams K, Haddad H, Baker A, Donaldson J, Pugliese C, Struthers C, Masters RG, Hendry PJ, Mesana T.
    Transplant Proc; 2007 Dec 27; 39(10):3334-9. PubMed ID: 18089382
    [Abstract] [Full Text] [Related]

  • 10. Monitoring of C0 and C2 blood concentrations of cyclosporine on the Roche Hitachi 902 analyzer.
    Yargui L, Berhoune A.
    Transplant Proc; 2009 Nov 27; 41(9):3713-9. PubMed ID: 19917373
    [Abstract] [Full Text] [Related]

  • 11. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Hübler M, Abd El Rahman MY, Miera O, Ewert P, Weng Y, Wei H, Krüdewagen B, Hetzer R, Berger F.
    J Heart Lung Transplant; 2006 Jun 27; 25(6):619-25. PubMed ID: 16730566
    [Abstract] [Full Text] [Related]

  • 12. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
    Bunnag S, Vareesangthip K, Ong-ajyooth L.
    J Med Assoc Thai; 2006 Aug 27; 89 Suppl 2():S228-34. PubMed ID: 17044476
    [Abstract] [Full Text] [Related]

  • 13. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P.
    Nephrol Dial Transplant; 2006 Jan 27; 21(1):197-202. PubMed ID: 16204301
    [Abstract] [Full Text] [Related]

  • 14. Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (<1 mg) samples.
    Noll BD, Coller JK, Somogyi AA, Morris RG, Russ GR, Hesselink DA, van Gelder T, Sallustio BC.
    Ther Drug Monit; 2011 Dec 27; 33(6):688-93. PubMed ID: 22105584
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the new heterogeneous ACMIA immunoassay for the determination of whole-blood cyclosporine concentrations in bone marrow, kidney, heart, and liver transplant recipients.
    Huet E, Morand K, Blanchet B, Astier A, Hulin A.
    Transplant Proc; 2004 Jun 27; 36(5):1317-20. PubMed ID: 15251322
    [Abstract] [Full Text] [Related]

  • 16. Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in Taiwan.
    Chou NK, Chen RJ, Ko WJ, Lin HL, Yu SY, Chen YS, Hsu RB, Lee CM, Lin FY, Wang SS.
    Transplant Proc; 2004 Oct 27; 36(8):2393-5. PubMed ID: 15561260
    [Abstract] [Full Text] [Related]

  • 17. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
    Barnard JB, Thekkudan J, Richardson S, Bittar MN, Martyszczuck R, Hasan J, Khasati N, Keevil B, Yonan N.
    J Heart Lung Transplant; 2006 May 27; 25(5):564-8. PubMed ID: 16678036
    [Abstract] [Full Text] [Related]

  • 18. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
    Delgado DH, Rao V, Hamel J, Miriuka S, Cusimano RJ, Ross HJ.
    J Heart Lung Transplant; 2005 Sep 27; 24(9):1343-6. PubMed ID: 16143255
    [Abstract] [Full Text] [Related]

  • 19. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP, Canter C, Shepherd R, Lassa-Claxton S, Nadler M.
    Pediatr Transplant; 2007 Aug 27; 11(5):524-9. PubMed ID: 17631021
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients.
    Konstandin MH, Sommerer C, Doesch A, Zeier M, Meuer SC, Katus HA, Dengler TJ, Giese T.
    Transpl Int; 2007 Dec 27; 20(12):1036-43. PubMed ID: 17850236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.